Published in Perit Dial Int on June 01, 2007
Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 1.55
Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol (2009) 1.06
Quality of life and mortality from a nephrologist's view: a prospective observational study. BMC Nephrol (2009) 0.90
Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients. Perit Dial Int (2011) 0.82
Infusion fluids contain harmful glucose degradation products. Intensive Care Med (2010) 0.79
Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients. Clinics (Sao Paulo) (2015) 0.78
Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol (2014) 0.77
Impact of peritoneal dialysis treatment on arterial stiffness and vascular changes in diabetic type 2 and nondiabetic patients with end-stage renal disease. Int J Nephrol (2013) 0.77
Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study. Clin Drug Investig (2013) 0.76
The effect of depression and health-related quality of life on the outcome of hemodialysis patients. Kidney Res Clin Pract (2012) 0.75
Insulin resistance in patients undergoing peritoneal dialysis: can we improve it? : editorial to: "the effect of HM-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis" by Fa Mee Doh et al. Cardiovasc Drugs Ther (2012) 0.75
Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis. Biomed Res Int (2015) 0.75
Mortality rates do not differ among patients prescribed various vitamin D agents. Perit Dial Int (2014) 0.75
The importance of using peritoneal equlibration test for the peritoneal transport type characterization in continuous ambulatory peritoneal dialysis patients. Bosn J Basic Med Sci (2010) 0.75
Factors Generating Glucose Degradation Products In Sterile Glucose Solutions For Infusion: Statistical Relevance Determination Of Their Impacts. Sci Rep (2017) 0.75
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int (2010) 3.53
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol (2008) 2.96
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int (2005) 2.78
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol (2008) 2.44
Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int (2005) 2.42
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 2.17
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 2.09
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant (2002) 2.05
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol (2002) 2.03
N‑terminal pro‑B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn (2015) 2.02
[In Process Citation]. Lakartidningen (2015) 2.01
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol (2009) 1.88
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. Nephrol Dial Transplant (2002) 1.82
Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial (2010) 1.82
Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol (2012) 1.80
Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int (2005) 1.80
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int (2006) 1.80
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) 1.69
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant (2006) 1.65
Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant (2008) 1.63
The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant (2004) 1.62
Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.61
Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis (2005) 1.57
Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr (2007) 1.55
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis (2009) 1.54
Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients. Perit Dial Int (2005) 1.53
Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med (2013) 1.47
Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. Obesity (Silver Spring) (2013) 1.47
Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int (2008) 1.46
How accurate is the description of transport kinetics in peritoneal dialysis according to different versions of the three-pore model? Perit Dial Int (2008) 1.46
Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. J Ren Nutr (2012) 1.43
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Bicarbonate-based peritoneal dialysis solution has less effect on ingestive behavior than lactate-based peritoneal dialysis solution. Perit Dial Int (2009) 1.41
Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. Blood Purif (2005) 1.40
Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle (2011) 1.39
[Ghrelin--new promising treatment in anorexia and catabolic conditions]. Lakartidningen (2010) 1.39
Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr (2008) 1.38
Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol (2009) 1.38
Left ventricular mechanical dyssynchrony in patients with different stages of chronic kidney disease and the effects of hemodialysis. Hemodial Int (2013) 1.38
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int (2013) 1.31
Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr (2004) 1.30
Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis (2009) 1.28
Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant (2002) 1.24
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.22
Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens (2011) 1.21
Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl (2002) 1.20
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med (2008) 1.17
Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell. Perit Dial Int (2007) 1.17